Lineage Cell Therapeutics, Inc. revenue
Lineage Cell Therapeutics, Inc.'s revenue was $14.6m in fiscal 2025, up 53.2% on the year before. Since fiscal 2009 ($1.9m) it has grown at a compound 13.5% a year. Over the last twelve months it was $13.1m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 4 | 4 | 4 | 4 | 5 | 7 | 6 | 3 | 5 | 4 | 2 | 4 | 15 | 9 | 9 | 15 | 13 |
| Growth on the year before | — | +92.6% | +19.6% | −11.7% | +13.2% | +18.3% | +34.2% | −15.8% | −41.6% | +44.2% | −29.5% | −48.1% | +137.7% | +238.7% | −39.2% | +6.2% | +53.2% | — |
| Gross profit | — | 4 | 4 | 3 | 4 | 4 | 6 | 6 | 3 | 5 | 3 | 1 | 3 | 14 | 8 | 9 | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,779 | 2,868 | 1,502 | 2,765 | 3,681 | 6,608 | 1,725 | 1,069 |
| Growth on the same quarter a year before | — | — | — | — | −2.6% | +130.4% | +14.8% | −61.3% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Collaboration Revenues | $13.6M | 93.5% | ▲ 67.0% |
| Event Based Milestones and Other Collaborative Revenue (part of Collaboration Revenues) | $7.2M | 52.6% | — |
| Upfront License Fees (part of Collaboration Revenues) | $6.4M | 47.4% | ▼ 20.9% |
| Royalties License and Other Revenues | $947,000 | 6.5% | ▼ 29.9% |
From Lineage Cell Therapeutics, Inc.'s 10-K filed March 5, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. | $13.1m | 19.9% | 7.5% |
| Alector, Inc. | $13.9m | -82.9% | -48.6% |
| Surrozen, Inc. | $11.5m | -8.8% | — |
| Keros Therapeutics, Inc. | $14.9m | -93.6% | — |
| Mindwalk Holdings Corp. | $11.3m | 47.8% | — |
| Relay Therapeutics, Inc. | $10.3m | 23.9% | 122.3% |
Compare with peers
- Alector, Inc. revenue
- Surrozen, Inc. revenue
- Keros Therapeutics, Inc. revenue
- Mindwalk Holdings Corp. revenue
- Relay Therapeutics, Inc. revenue
Head to head: ALEC vs LCTXLCTX vs SRZNKROS vs LCTX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies